JAMA Oncology

Papers
(The H4-Index of JAMA Oncology is 75. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
JAMA Oncology782
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer469
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply377
Error in Text318
Errors in Key Points and Abstract310
Stargazers299
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen285
Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer278
Overall Survival in the CAIRO5 Clinical Trial264
Piercing the Fog243
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply234
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?209
Nationwide Response to Carboplatin and Cisplatin Shortages in Lung Cancer203
Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply202
Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology191
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab191
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors188
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants175
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis161
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia157
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers157
Her Defiance154
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration150
Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention149
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab144
Tumor-Infiltrating Clonal Hematopoiesis and Pan-Cancer Prognosis in Patients With Solid Tumors144
The Multidisciplinary Cancer Conference141
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults139
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!139
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer136
Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses135
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer134
Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2 -Negative Early Breast Cancer128
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer126
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US124
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality—Reply116
The SOUND Randomized Clinical Trial Results115
Results of the TARGET-TP Randomized Clinical Trial113
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?109
An Atypical Rash on the Chest103
Immunotherapy Before Chemoradiotherapy—More Is Better?101
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers—Reply100
Clinical Trial Diversity—Will We Know It When We See It?97
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer97
Trauma96
Shifting Toward Precision Oncology in SCLC Treatment96
The Most Difficult Lesson From Cancer Just Might Be Its Most Valuable95
JAMA Oncology95
Unwinding of Medicaid Continuous Enrollment Exposes Millions to Disrupted Care—“Be Kind, Rewind”92
Coding Errors in Study of Eligibility for Lung Cancer Screening92
Challenges in Interpreting MELATORCH Trial Outcomes—Reply91
Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 201990
Error in Text89
Reassessing Treatment Outcomes Following Immune-Related Adverse Events—Reply86
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply86
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers86
Disparities in Trends of Gastroenteropancreatic Neuroendocrine Tumor Incidence86
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer84
JAMA Oncology84
National Trends in Dexrazoxane and Cardiovascular Health Care Utilization for Children With Acute Myeloid Leukemia83
Rethinking End Points in Modern Oncology Trials—Beyond the P Value83
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer82
Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma82
Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer82
Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy82
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis81
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms80
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?80
Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size80
Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active Surveillance79
Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories78
Variability in COVID-19 Vaccine Response Among People With Cancer78
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent76
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia76
Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic75
Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy75
0.43646001815796